Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAF p.Val600Glu (V600E) somatic mutation is mainly associated with MSS phenotype in metastatic colorectal cancer.

Cancer genomics & proteomics - 1 Jan 2000

Qiu Jinghua, Compagnone Marion, Laibe Sophy, Lagarde Arnaud, Goncalves Anthony, Turrini Olivier, Xerri Luc, Monges Geneviève, Olschwang Sylviane

Abstract excerpt

BACKGROUND: Oncogenic activation of EGF-signalling pathway is central to the progression of colorectal cancer. The use of mutations of the KRAS codons 12 and 13 as a selection biomarker for anti-endothelial growth factor receptor (EGFR) monoclonal antibody treatment is at present the first major step towards individualised treatment for patients with metastatic colorectal cancer. The impact of BRAF V600E mutation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Glutamic Acid

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Microsatellite Instability

Share to Neoplasm Metastasis

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Share to Valine

Source

Identifiers

PMID: 21289333

Genes

BRAF
KRAS
EGFR
EGF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAF p.Val600Glu (V600E) somatic mutation is mainly associated with MSS phenotype in metastatic colorectal cancer.PMID 21289333Read ↗

Targeting BRAF V600E in metastatic colorectal cancer: where are we today?Semantic proximity Read ↗

European expert panel consensus on the clinical management of BRAFV600E-mutant metastatic colorectal cancer.Semantic proximity Read ↗

KRAS mutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: an open issue.Semantic proximity Read ↗

Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation.Semantic proximity Read ↗

Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies.Semantic proximity Read ↗

The distinctive molecular, pathological and clinical characteristics of BRAF-mutant colorectal tumors.Semantic proximity Read ↗

The Evolving Treatment Landscape in BRAF-V600E-Mutated Metastatic Colorectal Cancer.Semantic proximity Read ↗

BRAF V600E and Non-V600E Mutations in RAS Wild-Type Metastatic Colorectal Cancer: Prognostic and Therapeutic Insights from a Nationwide, Multicenter, Observational Study (J-BROS)Semantic proximity Read ↗

Targeted Therapy for Colorectal Cancers With Non-V600 BRAF Mutations: Perspectives for Precision OncologySemantic proximity Read ↗

[BRAF gene mutation in wild-type KRAS patients with colorectal cancers].Semantic proximity Read ↗

Clinical Characterization of Targetable Mutations (BRAF V600E and KRAS G12C) in Advanced Colorectal Cancer-A Nation-Wide Study.Semantic proximity Read ↗

BRAF mutation in colorectal cancer: An updateSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.